pharmaphorum.com
Roche trumpets data for Soliris rival in NMOSD after US, EU filings -
Roche builds case for satralizumab for NMOSD as US and EU regulatory decisions loom, setting up a possible market showdown with Alexion’s blockbuster Soliris